Clinical trial results:
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.

Summary

EudraCT number	2019-004686-41
Trial protocol	GB GR CZ DE ES
Global end of trial date	02 July 2024

Results information

Result version number	v1 (current)
This version publication date	16 July 2025
First version publication date	16 July 2025

Trial information

Trial identification

Sponsor protocol code	IBA1160

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04817189
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Helsinn Healthcare SA
Sponsor organisation address	Via Pian Scairolo 9, Pazzallo-Lugano, Switzerland,
Public contact	HelpDesk, Institut biostatistiky a analýz, s.r.o., +420 515915 100, helpdesk@biostatistika.cz
Scientific contact	HelpDesk, Institut biostatistiky a analýz, s.r.o., +420 515915 100, helpdesk@biostatistika.cz
Sponsor organisation name	Helsinn Healthcare SA
Sponsor organisation address	Via Pian Scairolo 9, Pazzallo-Lugano, Switzerland,
Public contact	Alessandro Alonzi - Medical Advisor, Helsinn Healthcare SA, Alessandro.Alonzi@helsinn.com
Scientific contact	Alessandro Alonzi - Medical Advisor, Helsinn Healthcare SA, Alessandro.Alonzi@helsinn.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 June 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	02 July 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate if the use of NEPA (netupitant and palonosetron) in patients treated with IV moderately emetogenic chemotherapy and at high risk of CINV is more effective in preventing CINV than standard of care antiemetics over three cycles of chemotherapy

Protection of trial subjects:

The trial subjects were treated according to a common clinical practice. The only intervention in the trail was randomization.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 February 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 75
Country: Number of subjects enrolled	United Kingdom: 17
Country: Number of subjects enrolled	Czechia: 84
Country: Number of subjects enrolled	Germany: 97
Country: Number of subjects enrolled	Greece: 76
Country: Number of subjects enrolled	China: 53
Country: Number of subjects enrolled	Switzerland: 12
Worldwide total number of subjects	414
EEA total number of subjects	332

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	223
From 65 to 84 years	190
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

Start recruitment date (FPI): 01.02.2021
Stop recruitment date (LPI): 04.04.2024
Teritories: Czech Republic, Greece, Germany, Switzerland, United Kingdom, China, Spain

Pre-assignment

Screening details:

Screened patients: 427
Screen failure: 12
Total analysis set: 415

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	NEPA

Arm description:

One capsule of NEPA and Dexamethasone 8 mg (or equivalent corticosteroids) by the oral route on Day 1, approximately 1 hour before chemotherapy

Arm type	Experimental
Investigational medicinal product name	Akynzeo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

One capsule of NEPA by the oral route on Day 1, approximately 1 hour before chemotherapy

Arm title	Standard of care

Arm description:

- One of the 5-HT3-RAs recommended by MASCC/ESMO guidelines (standard of care), i.e. either:

Granisetron, 2 mg (oral) or 1 mg (IV)
OR
Palonosetron, 0.5 mg (oral) or 0.25mg (IV)
OR
Ondansetron, 16 mg (oral) or 8 mg (IV)
OR
Dolasetron 100 mg (oral)
OR
Tropisetron 5 mg (oral or IV)

- Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy

Arm type	Active comparator

Investigational medicinal product name	Granisetron
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Intravesical solution, Tablet
Routes of administration	Oral use

Dosage and administration details:

Granisetron, 2 mg (oral) or 1 mg (IV)

Number of subjects in period 1	NEPA	Standard of care
Started	206	208
Completed	171	177
Not completed	35	31
Discontinuation of chemotherapy treatment due to C	2	1
Adverse event, serious fatal	2	1
Consent withdrawn by subject	12	3
Adverse event, non-fatal	2	5
General or specific changes in the patient's condi	6	7
Non-qualification to perform consecutive cycles (e	3	10
Lost to follow-up	5	3
Protocol deviation	3	1

Baseline characteristics

Reporting groups

Reporting group title	Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	414	414	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	223	223	
From 65-84 years	190	190	
85 years and over	1	1	
Age continuous Units: years			
arithmetic mean	62.7		
standard deviation	± 11.5	-	
Gender categorical Units: Subjects			
Female	187	187	
Male	227	227	

Subject analysis sets

Subject analysis set title	Full Analysis set
Subject analysis set type	Full analysis

Subject analysis set description:

The Full Analysis Set (FAS) consists of 401 (NEPA: 196, SoC: 205) randomised patients to whom study drug was dispensed.

Reporting group values	Full Analysis set		
Number of subjects	401		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		

Adults (18-64 years)	210		
From 65-84 years	190		
85 years and over	1		
Age continuous			
Units: years			
arithmetic mean	62.7		
standard deviation	± 11.5		
Gender categorical			
Units: Subjects			
Female	180		
Male	221		

End points

End points reporting groups

Reporting group title	NEPA

Reporting group description:

One capsule of NEPA and Dexamethasone 8 mg (or equivalent corticosteroids) by the oral route on Day 1, approximately 1 hour before chemotherapy

Reporting group title	Standard of care

Reporting group description:

- One of the 5-HT3-RAs recommended by MASCC/ESMO guidelines (standard of care), i.e. either:

Granisetron, 2 mg (oral) or 1 mg (IV)
OR
Palonosetron, 0.5 mg (oral) or 0.25mg (IV)
OR
Ondansetron, 16 mg (oral) or 8 mg (IV)
OR
Dolasetron 100 mg (oral)
OR
Tropisetron 5 mg (oral or IV)

- Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy

Subject analysis set title	Full Analysis set
Subject analysis set type	Full analysis

Subject analysis set description:

The Full Analysis Set (FAS) consists of 401 (NEPA: 196, SoC: 205) randomised patients to whom study drug was dispensed.

Primary: The primary endpoint was complete response (defined as no emetic episode(s) and no use of rescue medication), during the overall phase (0-120h), after the start of the MEC administration over three consecutive cycles of chemotherapy.

End point title	The primary endpoint was complete response (defined as no emetic episode(s) and no use of rescue medication), during the overall phase (0-120h), after the start of the MEC administration over three consecutive cycles of chemotherapy.

End point description:

End point type	Primary

End point timeframe:

End of study

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	199		
Units: Probability (%)				
number (not applicable)	81.0	71.8		

Statistical analyses

Statistical analysis title	Probability to experience complete response

Statistical analysis description:

Primary endpoint was defined as complete response over three cycles of chemotherapy. To estimate the probability of complete response, a generalized linear model with covariates was used to evaluate the treatment effect of the NEPA compared to the SoC arm. Estimated OR from model was used to derive the difference in the probability of responders between treatment arms. Model-based statistics were used to calculate the difference in the probability to experience a "per cycle" complete response.

Comparison groups	NEPA v Standard of care
Number of subjects included in analysis	388
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.05
Method	a generalized linear model with covariat

Secondary: Complete response during the acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point title	Complete response during the acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:

acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	199		
Units: Probability (%)				
number (not applicable)	80.2	71.1		

Statistical analyses

No statistical analyses for this end point

Secondary: No emetic episode during the acute, delayed and overall phase and daily in each cycle

End point title	No emetic episode during the acute, delayed and overall phase and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:

the acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	199		
Units: Probability (%)				
number (not applicable)	95.4	86.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of vomiting episodes during the acute, delayed and overall phase and daily in each cycle

End point title	Number of vomiting episodes during the acute, delayed and overall phase and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:

acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	199		
Units: mean difference of episods per cycle				
number (confidence interval 95%)	-0.37 (-0.6 to -0.14)	0.0 (0.0 to 0.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: No rescue medication during the acute, delayed and overall phase and daily in each cycle

End point title	No rescue medication during the acute, delayed and overall phase and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:
acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	200		
Units: Probability (%)				
number (not applicable)	82.4	76.5		

Statistical analyses

No statistical analyses for this end point

Secondary: No significant nausea (maximum MAT scale = 2) during the acute, delayed and overall phase and daily in each cycle

End point title	No significant nausea (maximum MAT scale = 2) during the acute, delayed and overall phase and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:
acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	197		
Units: Probability (%)				
number (not applicable)	77.5	72.7		

Statistical analyses

No statistical analyses for this end point

Secondary: No nausea (MAT scale = 0) during the acute, delayed and overall phase and daily in each cycle

End point title	No nausea (MAT scale = 0) during the acute, delayed and overall phase and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:
acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	199		
Units: Probability (%)				
number (not applicable)	63.7	54.9		

Statistical analyses

No statistical analyses for this end point

Secondary: Complete protection (no emetic episode, no rescue medication and no significant nausea) during the acute, delayed and overall phase and daily in each cycle

End point title	Complete protection (no emetic episode, no rescue medication and no significant nausea) during the acute, delayed and overall phase and daily in each cycle

End point description:

End point type	Secondary

End point timeframe:
acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	198		
Units: Probability (%)				
number (not applicable)	71.8	62.4		

Statistical analyses

No statistical analyses for this end point

Secondary: Nausea and Vomiting-related quality of life indicators (through the Functional Living Index Emesis scale)

End point title	Nausea and Vomiting-related quality of life indicators (through the Functional Living Index Emesis scale)

End point description:

End point type	Secondary
End point timeframe: per cycle	

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	199		
Units: Mean difference between arms				
number (confidence interval 95%)	3.5 (0.05 to 6.96)	1.0 (1.0 to 1.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Collection of chemotherapy delays (Delay of chemotherapy administration due to CINV were also evaluated as part of health economic endpoints)

End point title	Collection of chemotherapy delays (Delay of chemotherapy administration due to CINV were also evaluated as part of health economic endpoints)
End point description:	

End point type	Secondary
End point timeframe: per cycle	

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	184	193		
Units: mean of delay days per patient				
arithmetic mean (standard deviation)	1.1 (± 3.49)	1.2 (± 3.45)		

Statistical analyses

No statistical analyses for this end point

Secondary: Collection of chemotherapy dose reductions

End point title	Collection of chemotherapy dose reductions
End point description:	

End point type	Secondary

End point timeframe:

per cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	184	193		
Units: Probability (%)				
number (not applicable)	3.0	4.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of daily doses of rescue medication administered for the treatment of CINV

End point title	Number of daily doses of rescue medication administered for the treatment of CINV

End point description:

End point type	Secondary

End point timeframe:

per cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	187	200		
Units: mean dose				
arithmetic mean (standard deviation)	16.3 (± 68.53)	46.3 (± 343.13)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of days of rescue medication administered for the treatment of CINV

End point title	Number of days of rescue medication administered for the treatment of CINV

End point description:

End point type	Other pre-specified
End point timeframe: per cycle	

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	187	200		
Units: mean of days and doses				
arithmetic mean (standard deviation)	0.5 (± 1.20)	0.5 (± 1.13)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of re-hydration bags given for at least grade 2 vomiting (more details below)

End point title	Number of re-hydration bags given for at least grade 2 vomiting (more details below)
End point description:	

End point type	Other pre-specified
End point timeframe: per cycle	

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	187	198		
Units: mean number of re-hydration bags per pat				
arithmetic mean (standard deviation)	0.0 (± 0)	0.0 (± 0.2)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: The number of days of unplanned hospitalisations related to CINV and department of hospitalization (type of ward)

End point title	The number of days of unplanned hospitalisations related to CINV and department of hospitalization (type of ward)
End point description:	

End point type	Other pre-specified

End point timeframe:
per cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	187	198		
Units: Mean number of days per patient				
arithmetic mean (standard deviation)	0.0 (± 0.07)	0.1 (± 0.75)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: The number of outpatient physician visits and health care consultations due to CINV (e.g., general practitioner)

End point title	The number of outpatient physician visits and health care consultations due to CINV (e.g., general practitioner)

End point description:

End point type	Other pre-specified

End point timeframe:
per cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	196	205		
Units: mean of visits per patient				
arithmetic mean (standard deviation)	0.0 (± 0.07)	0.0 (± 0.16)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: The number of unplanned laboratory tests including those at unplanned hospitalisations due to CINV

End point title	The number of unplanned laboratory tests including those at unplanned hospitalisations due to CINV

End point description:

End point type	Other pre-specified

End point timeframe:
per cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	187	198		
Units: mean number of tests				
arithmetic mean (standard deviation)	0.0 (± 0.07)	0.1 (± 0.46)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Discontinuation of chemotherapy treatment due to CINV

End point title	Discontinuation of chemotherapy treatment due to CINV
End point description:	
End point type	Other pre-specified
End point timeframe:	
per cycle	

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	196	205		
Units: patients	1	0		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Delay of chemotherapy administration due to CINV

End point title	Delay of chemotherapy administration due to CINV
End point description:	
End point type	Other pre-specified
End point timeframe:	
per cycle	

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0[1]	2		
Units: mean of days of delay				
arithmetic mean (standard deviation)	()	7 (± 0)		

Notes:

[1] - no patients discontinued from CINV

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Days of absence from work

End point title	Days of absence from work

End point description:

End point type	Other pre-specified

End point timeframe:

per cycle

End point values	NEPA	Standard of care		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	3		
Units: mean of days of absence				
arithmetic mean (standard deviation)	3 (± 3.08)	5.7 (± 4.16)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From a dose of antiemetic drug is administration to the end of the study, the day of Visit 4. Visit 4 is a visit on Day 5 of Cycle 3 or before the
start of the next programmed chemotherapy cycle.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	27.1

Reporting groups

Reporting group title	NEPA
Reporting group description: -	
Reporting group title	Standard of care

Reporting group description: -

Serious adverse events	NEPA	Standard of care	
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 196 (11.22%)	23 / 205 (11.22%)	
number of deaths (all causes)	2	2	
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Antibiotic therapy			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			

subjects affected / exposed	2 / 196 (1.02%)	2 / 205 (0.98%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Pyrexia			
subjects affected / exposed	3 / 196 (1.53%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 196 (0.51%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chills			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 196 (0.51%)	2 / 205 (0.98%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Haemoptysis			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngospasm			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Throat irritation			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Oxygen saturation decreased			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular accident			

subjects affected / exposed	2 / 196 (1.02%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphasia			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery occlusion			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianopia			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	6 / 196 (3.06%)	5 / 205 (2.44%)	
occurrences causally related to treatment / all	0 / 6	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 196 (1.02%)	5 / 205 (2.44%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	3 / 196 (1.53%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vomiting			

subjects affected / exposed	1 / 196 (0.51%)	3 / 205 (1.46%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	1 / 196 (0.51%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyper-transaminasaemia			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal failure			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Musculoskeletal chest pain			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Infection			
subjects affected / exposed	1 / 196 (0.51%)	2 / 205 (0.98%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 196 (0.51%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Abscess oral			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	1 / 196 (0.51%)	0 / 205 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lower respiratory tract infection			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ludwig angina			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Tumour lysis syndrome			
subjects affected / exposed	0 / 196 (0.00%)	1 / 205 (0.49%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	NEPA	Standard of care	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	174 / 196 (88.78%)	183 / 205 (89.27%)	
Vascular disorders			
Peripheral coldness			
subjects affected / exposed	5 / 196 (2.55%)	4 / 205 (1.95%)	
occurrences (all)	7	6	
Hypotension			
subjects affected / exposed	2 / 196 (1.02%)	5 / 205 (2.44%)	
occurrences (all)	2	5	
Nervous system disorders			

Paraesthesia			
subjects affected / exposed	33 / 196 (16.84%)	26 / 205 (12.68%)	
occurrences (all)	49	43	
Dizziness			
subjects affected / exposed	24 / 196 (12.24%)	15 / 205 (7.32%)	
occurrences (all)	31	16	
Neuropathy peripheral			
subjects affected / exposed	15 / 196 (7.65%)	20 / 205 (9.76%)	
occurrences (all)	24	28	
Headache			
subjects affected / exposed	18 / 196 (9.18%)	15 / 205 (7.32%)	
occurrences (all)	25	22	
Hypoaesthesia			
subjects affected / exposed	11 / 196 (5.61%)	20 / 205 (9.76%)	
occurrences (all)	14	24	
Neurotoxicity			
subjects affected / exposed	10 / 196 (5.10%)	8 / 205 (3.90%)	
occurrences (all)	11	8	
Dysgeusia			
subjects affected / exposed	8 / 196 (4.08%)	7 / 205 (3.41%)	
occurrences (all)	8	10	
Polyneuropathy			
subjects affected / exposed	6 / 196 (3.06%)	7 / 205 (3.41%)	
occurrences (all)	9	7	
Somnolence			
subjects affected / exposed	7 / 196 (3.57%)	5 / 205 (2.44%)	
occurrences (all)	10	10	
Cold dysaesthesia			
subjects affected / exposed	4 / 196 (2.04%)	3 / 205 (1.46%)	
occurrences (all)	4	4	
Peripheral sensory neuropathy			
subjects affected / exposed	5 / 196 (2.55%)	2 / 205 (0.98%)	
occurrences (all)	8	2	
Taste disorder			
subjects affected / exposed	2 / 196 (1.02%)	4 / 205 (1.95%)	
occurrences (all)	2	5	

Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	8 / 196 (4.08%)	7 / 205 (3.41%)	
occurrences (all)	8	8	
Anaemia			
subjects affected / exposed	3 / 196 (1.53%)	8 / 205 (3.90%)	
occurrences (all)	3	8	
Leukocytosis			
subjects affected / exposed	1 / 196 (0.51%)	4 / 205 (1.95%)	
occurrences (all)	1	4	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	54 / 196 (27.55%)	46 / 205 (22.44%)	
occurrences (all)	83	78	
Asthenia			
subjects affected / exposed	25 / 196 (12.76%)	21 / 205 (10.24%)	
occurrences (all)	33	27	
General physical health deterioration			
subjects affected / exposed	3 / 196 (1.53%)	12 / 205 (5.85%)	
occurrences (all)	3	12	
Pain			
subjects affected / exposed	6 / 196 (3.06%)	7 / 205 (3.41%)	
occurrences (all)	9	10	
Pyrexia			
subjects affected / exposed	4 / 196 (2.04%)	7 / 205 (3.41%)	
occurrences (all)	4	10	
Oedema peripheral			
subjects affected / exposed	1 / 196 (0.51%)	8 / 205 (3.90%)	
occurrences (all)	1	8	
Chest pain			
subjects affected / exposed	2 / 196 (1.02%)	4 / 205 (1.95%)	
occurrences (all)	2	4	
Chills			
subjects affected / exposed	1 / 196 (0.51%)	4 / 205 (1.95%)	
occurrences (all)	1	4	
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	4 / 196 (2.04%)	7 / 205 (3.41%)	
occurrences (all)	4	7	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	40 / 196 (20.41%)	48 / 205 (23.41%)	
occurrences (all)	63	66	
Constipation			
subjects affected / exposed	41 / 196 (20.92%)	29 / 205 (14.15%)	
occurrences (all)	52	42	
Abdominal pain			
subjects affected / exposed	19 / 196 (9.69%)	25 / 205 (12.20%)	
occurrences (all)	26	31	
Nausea			
subjects affected / exposed	15 / 196 (7.65%)	17 / 205 (8.29%)	
occurrences (all)	22	32	
Dyspepsia			
subjects affected / exposed	9 / 196 (4.59%)	6 / 205 (2.93%)	
occurrences (all)	12	10	
Dry mouth			
subjects affected / exposed	8 / 196 (4.08%)	6 / 205 (2.93%)	
occurrences (all)	10	8	
Abdominal discomfort			
subjects affected / exposed	3 / 196 (1.53%)	10 / 205 (4.88%)	
occurrences (all)	4	11	
Abdominal pain upper			
subjects affected / exposed	6 / 196 (3.06%)	2 / 205 (0.98%)	
occurrences (all)	6	2	
Stomatitis			
subjects affected / exposed	4 / 196 (2.04%)	4 / 205 (1.95%)	
occurrences (all)	5	4	
Dysphagia			
subjects affected / exposed	1 / 196 (0.51%)	6 / 205 (2.93%)	
occurrences (all)	3	9	
Eructation			

subjects affected / exposed	5 / 196 (2.55%)	2 / 205 (0.98%)	
occurrences (all)	6	2	
Gastrooesophageal reflux disease			
subjects affected / exposed	5 / 196 (2.55%)	1 / 205 (0.49%)	
occurrences (all)	5	1	
Hypoaesthesia oral			
subjects affected / exposed	2 / 196 (1.02%)	4 / 205 (1.95%)	
occurrences (all)	2	5	
Vomiting			
subjects affected / exposed	2 / 196 (1.02%)	4 / 205 (1.95%)	
occurrences (all)	2	5	
Abdominal distension			
subjects affected / exposed	4 / 196 (2.04%)	1 / 205 (0.49%)	
occurrences (all)	4	2	
Flatulence			
subjects affected / exposed	0 / 196 (0.00%)	4 / 205 (1.95%)	
occurrences (all)	0	7	
Oral pain			
subjects affected / exposed	0 / 196 (0.00%)	4 / 205 (1.95%)	
occurrences (all)	0	4	
Paraesthesia oral			
subjects affected / exposed	0 / 196 (0.00%)	4 / 205 (1.95%)	
occurrences (all)	0	5	
Respiratory, thoracic and mediastinal disorders			
Hiccups			
subjects affected / exposed	10 / 196 (5.10%)	4 / 205 (1.95%)	
occurrences (all)	11	5	
Epistaxis			
subjects affected / exposed	5 / 196 (2.55%)	8 / 205 (3.90%)	
occurrences (all)	5	10	
Dyspnoea			
subjects affected / exposed	4 / 196 (2.04%)	6 / 205 (2.93%)	
occurrences (all)	4	7	
Cough			

subjects affected / exposed	5 / 196 (2.55%)	1 / 205 (0.49%)	
occurrences (all)	5	1	
Oropharyngeal pain			
subjects affected / exposed	5 / 196 (2.55%)	1 / 205 (0.49%)	
occurrences (all)	5	1	
Throat irritation			
subjects affected / exposed	1 / 196 (0.51%)	4 / 205 (1.95%)	
occurrences (all)	2	7	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	9 / 196 (4.59%)	12 / 205 (5.85%)	
occurrences (all)	10	15	
Erythema			
subjects affected / exposed	5 / 196 (2.55%)	7 / 205 (3.41%)	
occurrences (all)	5	13	
Rash			
subjects affected / exposed	9 / 196 (4.59%)	2 / 205 (0.98%)	
occurrences (all)	10	2	
Pruritus			
subjects affected / exposed	3 / 196 (1.53%)	5 / 205 (2.44%)	
occurrences (all)	3	6	
Dry skin			
subjects affected / exposed	1 / 196 (0.51%)	5 / 205 (2.44%)	
occurrences (all)	1	6	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	4 / 196 (2.04%)	8 / 205 (3.90%)	
occurrences (all)	5	10	
Restlessness			
subjects affected / exposed	2 / 196 (1.02%)	4 / 205 (1.95%)	
occurrences (all)	2	6	
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	11 / 196 (5.61%)	16 / 205 (7.80%)	
occurrences (all)	13	26	
Arthralgia			

subjects affected / exposed	6 / 196 (3.06%)	7 / 205 (3.41%)	
occurrences (all)	6	7	
Muscle spasms			
subjects affected / exposed	4 / 196 (2.04%)	7 / 205 (3.41%)	
occurrences (all)	6	12	
Bone pain			
subjects affected / exposed	7 / 196 (3.57%)	3 / 205 (1.46%)	
occurrences (all)	7	3	
Limb discomfort			
subjects affected / exposed	6 / 196 (3.06%)	2 / 205 (0.98%)	
occurrences (all)	7	2	
Back pain			
subjects affected / exposed	3 / 196 (1.53%)	4 / 205 (1.95%)	
occurrences (all)	3	7	
Muscular weakness			
subjects affected / exposed	4 / 196 (2.04%)	2 / 205 (0.98%)	
occurrences (all)	4	2	
Myalgia			
subjects affected / exposed	2 / 196 (1.02%)	4 / 205 (1.95%)	
occurrences (all)	3	6	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	23 / 196 (11.73%)	30 / 205 (14.63%)	
occurrences (all)	33	47	
Hypokalaemia			
subjects affected / exposed	5 / 196 (2.55%)	3 / 205 (1.46%)	
occurrences (all)	5	3	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported